Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Rules, for a period to be subsequently determined by the Speaker, in eac…
The CommonGround for Affordable Health Care Act would (1) extend and modify the enhanced premium tax credit (the ACA advance premium tax credit) for a limited period (taxable year 2026) with a new schedule of premium percentage caps by income tiers, (2) add multiple “guardrails” aimed at preventing fraudulent enrollments in Exchange plans (including new civil and criminal penalties for agents/brokers, verification requirements for agent-/broker-assisted enrollments, requirements to register and audit marketing organizations, and a Death Master File check to remove deceased enrollees), (3) extend the 2026 open enrollment window for Exchanges to Nov 1, 2025–Mar 19, 2026 and require Exchanges to notify individuals of the amount of premium tax credits before enrollment, (4) impose new transparency, contracting, audit, and remuneration rules on pharmacy benefit managers (PBMs) for Medicare Part D and MA–PD plans beginning in 2029 (including reporting requirements, limits on non–service-fee remuneration, audit rights, enforcement provisions, and funding for CMS/OIG implementation), and (5) establish expedited floor procedures in both Houses for consideration of subsequent bipartisan “enhanced premium tax credit reform” legislation.
Some effective dates and implementation details are left to the Secretary by regulation and the bill appropriates specified funds for implementation and oversight.
On content alone this is a broad, complex package that combines a costly subsidy extension with major regulatory overhauls and enhanced enforcement powers affecting multiple well-organized industries. While individual pieces (open enrollment extension, some fraud protections, targeted transparency) might be enacted separately, the combined bill as presented mixes high-cost, high-controversy provisions with significant implementation complexity. That mix reduces the chance of enactment without substantial revision, offsets, or a narrower legislative vehicle. The procedural fast-track language for future premium-credit bills is also unusual and could be contested as a matter of chamber rules, further complicating enactment.
How solid the drafting looks.
Subsidy extension and eligibility: liberals and centrists generally support a 2026 extension for affordability; conservatives oppose expanded taxpayer-funded subsidies (particularly if eligibility reaches higher incomes).
Subsidy extension and eligibility: liberals and centrists generally support a 2026 extension for affordability; conservatives oppose expanded taxpayer-funded subsidies (particularly if eligibility reaches higher incomes…
A mainstream liberal/left-leaning observer would likely view the bill as mostly positive because it extends enhanced premium tax credits for 2026, increases affordability for many enrollees, strengthens consumer protections and transparency, and includes PBM accountability measures that could reduce drug costs.
They would welcome provisions that notify consumers of credit amounts prior to enrollment and the extended open enrollment window.
However, they would be cautious about aggressive criminal and civil penalties on agents/brokers and any verification processes that could unintentionally create enrollment barriers for low‑income, elderly, disabled, or limited-English-proficient consumers.
A centrist/moderate would likely see the bill as a pragmatic, mixed package: it provides a short-term extension of affordability assistance and strengthens integrity and transparency measures, while also adding regulatory obligations and enforcement steps that require careful administration.
They would appreciate the bipartisan process incentives (the expedited consideration rules) but want clearer fiscal estimates and implementation planning to avoid unintended consequences.
Overall a centrist would be cautiously favorable if the bill includes guardrails to limit administrative burden, ensures due process, and provides adequate funding and analytic oversight.
A mainstream conservative/conservative-leaning observer would likely oppose or be skeptical of the bill overall.
They would object to continued or expanded taxpayer‑funded premium subsidies (especially if eligibility extends toward higher incomes), view PBM contracting and remuneration restrictions as federal overreach into private market agreements, and be wary of increased regulatory and reporting burdens.
They may welcome some integrity provisions (fraud penalties, verification, removal of deceased enrollees) but would be concerned about the cost, expanded federal authority, and new interventionist rules for PBMs and marketing organizations.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone this is a broad, complex package that combines a costly subsidy extension with major regulatory overhauls and enhanced enforcement powers affecting multiple well-organized industries. While individual pieces (open enrollment extension, some fraud protections, targeted transparency) might be enacted separately, the combined bill as presented mixes high-cost, high-controversy provisions with significant implementation complexity. That mix reduces the chance of enactment without substantial revision, offsets, or a narrower legislative vehicle. The procedural fast-track language for future premium-credit bills is also unusual and could be contested as a matter of chamber rules, further complicating enactment.
The bill has not accumulated any surfaced votes yet.
Subsidy extension and eligibility: liberals and centrists generally support a 2026 extension for affordability; conservatives oppose expand…
On content alone this is a broad, complex package that combines a costly subsidy extension with major regulatory overhauls and enhanced enf…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for CommonGround for Affordable Health Care Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.